Feature | June 06, 2013

Impact of Sequestration on the National Institutes of Health

NIH says every area of research will be impacted with $1.55 billion in budget cuts

National Institute of Health Campus

June 6, 2013 — The National Institutes of Health (NIH), the nation’s medical research agency and the leading supporter of biomedical research in the world, said all of its clinical programs will be effected by $1.55 billion in NIH budget cuts due to sequestration. On March 1, 2013, as required by statute, President Obama signed an order initiating sequestration. This requires NIH to cut 5 percent, or $1.55 billion, of its fiscal year (FY) 2013 budget. NIH must apply the cut evenly across all programs, projects and activities (PPAs), which are primarily NIH institutes and centers. 


More than 80 percent of the NIH's budget goes to over 300,000 research personnel at more than 2,500 universities and research institutions throughout the United States. In addition, about 6,000 scientists work in NIH’s own Intramural Research laboratories, most of which are on the NIH main campus in Bethesda, Md. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research.


The Estimated Numbers


In comparing FY 2013 figures to FY 2012, NIH has arrived at the following estimates for cuts.


Approximately 700 fewer competitive research project grants issued
Approximately 750 fewer new patients admitted to the NIH Clinical Center
No increase in stipends for National Research Service Award recipients in FY2013

 


The Impact of Cuts


NIH said the cuts will delay medical research progress. Medical breakthroughs do not happen overnight, NIH said.  In almost all instances, breakthrough discoveries result from years of incremental research to understand how disease starts and progresses. Even after the cause and potential drug target of a disease is discovered, NIH said it takes on average 13 years and $1 billion to develop a treatment for that target.


Therefore, cuts to research are delaying progress in medical breakthroughs, including:


Development of better cancer drugs that zero in on a tumor with fewer side effects,
Research on a universal flu vaccine that could fight every strain of influenza without needing a yearly shot, and
Prevention of debilitating chronic conditions that are costly to society and delay development of more effective treatments for common and rare diseases affecting millions of Americans.

 


Reductions to noncompeting research project grants (RPG) vary. The NIH-wide average is -4.7 percent.


Institutes and centers have flexibility to accommodate the new budget level in a fashion that allows them to meet their scientific and strategic goals. As noted above, there are different percentages for different Institutes and Centers (ICs), and in some cases for different mechanisms within an IC (RPGs, Centers, etc.). In addition, there may be reductions to grants for reasons other than sequestration, as is the case every year.


The impact on NIH’s intramural research at its Bethesda, Md., campus and off-campus facilities is substantial, NIH said. This is because it applies retroactively to spending since Oct. 1, 2012. That can double the effect — a full year’s cut has to be absorbed in less than half a year.


There are no current plans to furlough or cut employees. At present, HHS is pursuing non-furlough administrative cost savings such as delayed/forgone hiring and reducing administrative services contracts so that furloughs and layoffs can be avoided. Additionally, employee salaries at NIH make up a very small percentage (only 7 percent) of the NIH budget.


Approximately 750 fewer new patients will be admitted to the NIH Clinical Center hospital in 2013 or a decrease from 10,695 new patients in 2012 to approximately 9,945 new patients in 2013. While much of this decrease is due to funding, clinical activity is always a dynamic situation with multiple drivers.


For more information: www.nih.gov


Related Content

Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
UNC, biomarkers, severe heart disease, fructosamine, LDL cholesterol, Nichols
News | Cardiac Diagnostics| July 21, 2015
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
NeoStem, PreSERVE study, AMI, ACC.15, NBS10, CD34 stem cells
Feature | Heart Failure| July 17, 2015
NeoStem Inc. presented updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study...
Overlay Init